Back to News
Market Impact: 0.4
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
Source: PR Newswire
Healthcare & BiotechRegulation & Legislation
TRYNGOLZA (olezarsen) received a positive CHMP opinion based on Phase 3 CORE and CORE2 results. The reported results showed a statistically significant placebo-adjusted mean reduction of up to 72% in triglyceride levels and an 85% reduction in the rate of acute pancreatitis events versus the article’s unspecified comparator.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
More News
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- MSCI Ignites Indonesia Market Reckoning After Months of Warnings
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- Kimberly-Clark is having its best week in four years. Here's what is propelling shares higher
- Trump waives many Russia-related sanctions, tariffs before they were to take effect under new law
- Norway's $2 trillion wealth fund was frozen out of major defense companies. That may be about to change